CONCLUSION
This TLP coating represents the first surface coating to reduce thrombosis under physiological arterial
flow in vivo without the use of soluble anticoagulants. This coating technology offers the potential to sig-
94
nificantly reduce anticoagulation in patients while preventing thrombotic occlusion and biofouling of
medical devices.